Liver Cancer (Hepatocellular Carcinoma) clinical trials in New York
47 active Liver Cancer (Hepatocellular Carcinoma) trials with a site in New York. Describe your situation to see which ones look like a fit.
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- The Dragon PLC Trial (DRAGON-PLC)
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- HOPE Against Cancer Recurrence in HCC
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
- Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- A Phase 1 Study of the Safety and Tolerability of CTX-10726
- A Study of ZW251 in Participants With Advanced Solid Tumors
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
- National Liver Cancer Screening Trial
- GNOS-PV02 Personalized Neoantigen Vaccine and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
- Observational Study Protocol: LIVER-R
- LTFU for All Cell and Gene Therapy Studies
- FAST (Focused Abbreviated Screening Technique)-MRI Study
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.